SHARON DELLINGER: Open Payments
NPI 1932213584 · NEW BRITAIN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,485 in 77 payments from 16 companies in 2025. Trend: 2023 $995 · 2024 $1,636 · 2025 $1,485
Food & beverage: $1,398Education: $87
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $377 |
| Janssen Biotech, Inc. | 7 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $175 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $166 |
| Phathom Pharmaceuticals, Inc. | 8 | $100 |
| Madrigal Pharmaceuticals | 4 | $98 |
| Celltrion USA Inc. | 3 | $72 |
| Ardelyx, Inc. | 3 | $72 |
| GENZYME CORPORATION | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
Products named: TREMFYA, XIFAXAN, VIBERZI, LINZESS, ENTYVIO, VOQUEZNA, REZDIFFRA, DUPIXENT.
Industry payments across CT — which companies pay providers there.
